|
HER2-TPMC proves to be a reasonable alternative for HER2-positive cancer chemotherape
Announcing a new article publication for BIO Integration journal. Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life.
More... |
| All times are GMT -7. The time now is 09:50 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021